Busch J, Hammer M, Brunkhorst R, Wagener P
Zentrum Innere Medizin, Med.-Hochschule Hannover.
Z Rheumatol. 1988 May-Jun;47(3):156-60.
We measured the amount of plasma endotoxin in 95 patients with inflammatory rheumatic diseases (42 with ankylosing spondylitis; 12 with possible ankylosing spondylitis; 41 with rheumatoid arthritis) and in 16 patients with Crohn's disease with a quantitative Limulus assay. Significantly increased mean values were found in inflammatory rheumatic diseases and in Crohn's disease. Between 31% and 50% of the patients had endotoxin values higher than 10 pg/ml--none of the controls had such values. Patients on regular treatment with NSAIDS had higher amounts of endotoxin again. From our results we discuss an intestinal involvement in inflammatory rheumatic diseases. An inflammation of the gut with an increased permeability seems to be responsible for the raised plasma endotoxin levels compared to healthy controls. NSAIDs probably contribute to the increased permeability of the gut.
我们采用鲎试剂定量法对95例炎性风湿性疾病患者(42例强直性脊柱炎;12例可能的强直性脊柱炎;41例类风湿关节炎)及16例克罗恩病患者的血浆内毒素含量进行了测定。结果发现,炎性风湿性疾病患者和克罗恩病患者的平均内毒素含量显著升高。31%至50%的患者内毒素值高于10 pg/ml,而对照组中无一例如此。规律服用非甾体抗炎药(NSAIDS)的患者内毒素含量再次升高。基于我们的研究结果,我们讨论了炎性风湿性疾病中的肠道受累情况。与健康对照组相比,肠道炎症伴通透性增加似乎是血浆内毒素水平升高的原因。非甾体抗炎药可能促使肠道通透性增加。